[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Mlika M, Chelly I, Benrhouma M, Haouet S, Horchani A, Zitouna MM, Kchir N: A Primary Testicular Diffuse Large B-cell Lymphoma Belonging to the Germinal Center B-cell-like Group. J Clin Med Res; 2010 Feb;2(1):47-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Primary Testicular Diffuse Large B-cell Lymphoma Belonging to the Germinal Center B-cell-like Group.
  • Testicular lymphoma was first reported by Malassez and Curling in 1866.
  • Primary testicular lymphoma constitutes only 1 - 7% of all testicular neoplasms and less than 1% of all non Hodgkin lymphoma.
  • The authors report a new case of primary testicular lymphoma and highlight its diagnostic and therapeutic challenge.
  • Radiological findings consisted in multiple hypoechoic masses that corresponded in histological examination to a diffuse intratubular lymphomatous infiltration situated away from the spermatic cord, the epididymis, ductuli efferentes and rete testis.
  • Immunohistochemical study showed positivity for leukocytic common antigen (CD45), B-cell marker (CD20) and bcl 6.
  • The patient underwent full staging for lymphoma showing no evidence of extra-testicular involvement by lymphoma and no lymph nodes.
  • The diagnosis of stage I primary testicular large B-cell lymphoma of germinal center B-cell-like group was made.
  • The patient is now treated by chemotherapy.
  • Primary testicular lymphoma is a rare tumour whose diagnosis is based on histological findings.
  • Treatment modalities consist in surgical excision, chemotherapy and radiation therapy but the accurate procedures are not standardized.
  • KEYWORDS: Testicular lymphoma; Germinal center; B-cell.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22457702.001).
  • [ISSN] 1918-3003
  • [Journal-full-title] Journal of clinical medicine research
  • [ISO-abbreviation] J Clin Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3299176
  •  go-up   go-down


2. Petrescu A, Dobrea C, Vasilică M, Andrei F, Niculescu L: Primary malignant lymphoma of the testis. Rom J Morphol Embryol; 2005;46(2):83-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant lymphoma of the testis.
  • Primary testicular lymphomas are rare entities representing 1-2% of non-Hodgkin lymphoma (NHML) and 1-7% of malignant testicular tumors and they are the most common testicular tumors in men older than 50 years of age.
  • Orchectomy was performed as first therapeutic and diagnostic purpose.
  • All patients were clinically staged according to the Ann Arbor criteria in IE and IIID stage and received a doxorubicin based chemotherapy regimen (CHOP, MTX, CVP, and Leukeran).
  • A standard chemotherapy protocol has not been used because of reduced number of patients.
  • Alphafetoprotein was positive in seminal tubes and negative in tumor, NK1 in small lymphocyte and negative in tumor and L26 diffuse positive in tumor.
  • CLA diffuse positive in tumor.
  • CONCLUSIONS: The diagnosis was of NHML in 6 cases and for 2 secondary involvement of hematopoietic malignancy (myeloid sarcoma and leukemia).
  • Lymphoma cases were typed using REAL classification as small and large B-cell lymphoma.
  • Unfavorable evolution with 6 months relapse and one death prove a more aggressive evolution of primitive testicular lymphoma.
  • [MeSH-major] Lymphoma / pathology. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286990.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


3. Kasai T, Moriyama K, Tsuji M, Uema K, Sakurai N, Akazawa S: [Metachronous bilateral primary malignant lymphoma of the testis: a case report]. Nihon Hinyokika Gakkai Zasshi; 2000 May;91(5):526-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metachronous bilateral primary malignant lymphoma of the testis: a case report].
  • Left high orchiectomy was performed under the diagnosis of primary testicular tumor.
  • Histological findings revealed non-Hodgkin's lymphoma (NHL) of diffuse, mixed type, B cells.
  • About 3 years and a month earlier, he had undergone right high orchiectomy and postoperative radiotherapy (inverted Y irradiation) and chemotherapy (CHOP 5 cycles) for a right testicular tumor whose histological findings were NHL of diffuse, large cell type, B cells.
  • Metachronous bilateral primary malignant lymphoma of the testis is very rare and we discussed each tumor origin by using IgH gene (IgJHDNA) rearrangement as a tumor specific marker of B cell lineage malignant lymphoma.
  • We discussed the clonality of IgJHDNA rearrangement using polymerase chain reaction (PCR) in each paraffin fragment diagnosed pathologically as NHL of B cell origin.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Neoplasms, Second Primary. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Humans. Immunoglobulin Heavy Chains / genetics. Male

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10853335.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


Advertisement
4. Mazloom A, Fowler N, Medeiros LJ, Iyengar P, Horace P, Dabaja BS: Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma; 2010 Jul;51(7):1217-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience.
  • The purpose of this study was to assess the clinicopathologic characteristics and outcomes in patients with diffuse large B-cell lymphoma (DLBCL) of the testis, and to assess the impact of changes in the therapeutic approach that have occurred over the years.
  • Factors analyzed included: age, clinical stage, B-symptoms, serum levels of lactate dehydrogenase (LDH), beta(2)-microglobulin, treatment received, and outcome.
  • Immunophenotypic data were available for 43 cases, all of which showed B-cell lineage.
  • The 5-year OS and PFS for patients after 2000, treated predominantly with R-CHOP, intrathecal chemotherapy (ITC), and scrotal radiotherapy (RT), were 86.6% and 59.3%, respectively.
  • This is compared to 56.3% and 51.7%, respectively, for patients treated between 1977 and 1999 with doxorubicin based chemotherapy without rituximab, who were not uniformly treated with ITC.
  • Patients treated prior to 1977 had an OS and PFS of 15.4% and 15.4%, respectively, and were not treated with doxorubicin based chemotherapy or ITC (p = 0.019 for OS and p = 0.138 for PFS).
  • R-CHOP based chemotherapy with intrathecal chemotherapy and scrotal RT is associated with an improved OS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Prednisone / administration & dosage. Radiotherapy Dosage. Rituximab. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Young Adult. beta 2-Microglobulin / blood

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Jul;51(7):1159-60 [20497004.001]
  • (PMID = 20443676.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / beta 2-Microglobulin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone
  •  go-up   go-down


5. Li D, Mi C, Zhao Y, Wang YL, Ma Y, Li YY, Xiang MH: [Primary diffuse large B-cell lymphoma of testis: a clinicopathologic study of 14 cases]. Zhonghua Bing Li Xue Za Zhi; 2007 Jul;36(7):461-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell lymphoma of testis: a clinicopathologic study of 14 cases].
  • OBJECTIVE: To study the clinicopathologic features, immunohistochemical findings and prognosis of primary diffuse large B-cell lymphoma (DLBCL) of testis.
  • METHODS: Fourteen cases of primary DLBCL of testis, diagnosed according to the 2001 World Health Organization staging standards for hematopoietic and lymphoid tumors, were retrospectively studied.
  • The patients usually presented with unilateral painless enlargement of testis.
  • Histologically, the lymphoma cells of all cases showed a centroblastic appearance.
  • One case belonged to the germinal center B cell-like subtype on immunohistochemical study, while the remaining 13 cases were classified as non-germinal center B cell-like subtype.
  • CONCLUSIONS: Most cases with primary DLBCL of testis were of peripheral activated B-cell origin.
  • Accurate pathologic diagnosis relies on detailed histologic examination and immunohistochemical study.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD20 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Germinoma / drug therapy. Germinoma / metabolism. Germinoma / pathology. Germinoma / surgery. Humans. Male. Middle Aged. Neprilysin / metabolism. Orchiectomy. Prednisone / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / metabolism. Retrospective Studies. Seminoma / pathology. Survival Rate. Tumor Suppressor Protein p53 / metabolism. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17845759.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


6. Autorino R, Lamendola MG, De Sio M, Di Trolio RA, Ferraraccio F, Di Lorenzo G: A complete response with rituximab in metastatic diffuse large B-cell lymphoma of the testis: case report. Int J Immunopathol Pharmacol; 2007 Apr-Jun;20(2):401-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A complete response with rituximab in metastatic diffuse large B-cell lymphoma of the testis: case report.
  • Primary testicular lymphoma is an uncommon testicular tumour.
  • We present a case of a primary non-Hodgkin lymphoma of the testis, describing its clinical and pathological features and discussing our treatment strategy.
  • Light microscopy demonstrated the classic appearance of a diffuse large B-cell lymphoma.
  • No evidence of extra-testicular involvement by lymphoma was found.
  • The histologic analysis confirmed diagnosis of CD-20 positive B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Agents / pharmacology. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Testicular Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624254.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


7. Vural F, Cagirgan S, Saydam G, Hekimgil M, Soyer NA, Tombuloglu M: Primary testicular lymphoma. J Natl Med Assoc; 2007 Nov;99(11):1277-82
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular lymphoma.
  • We evaluated clinical features, management and survival of 12 patients with primary testicular non-Hodgkin's lymphoma presented to our hematology unit between January 1992 and July 2006, retrospectively.
  • In the majority of cases, orchidectomy was performed as diagnostic and first-line therapeutic procedures.
  • Dominant histological subtype was diffuse large B-cell non-Hodgkin's lymphoma.
  • All the patients received doxorubicin-based chemotherapy and achieved complete remission.
  • The addition of rituximab and central nervous system prophylaxis with intrathecal combined chemotherapy containing methotrexate, cytarabine and dexametasone were applied to three patients who were recently admitted.
  • Because of the spreading nature and relapse probability at different sites, including central nervous system and contralateral testis, systemic treatment with doxorubicin-based chemotherapy with or without prophylaxis for contralateral testis and the central nervous system seems to improve the outcome of primary testicular lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide. Disease Progression. Doxorubicin. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Orchiectomy. Prednisone. Prognosis. Retrospective Studies. Survival. Treatment Outcome. Turkey. Vincristine

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Lymphoma. 2001 Sep;2(2):109-15 [11707851.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):20-7 [12506165.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Acta Radiol Oncol Radiat Phys Biol. 1979;18(6):572-76 [543449.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1578-84 [6989476.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2095-102 [7296517.001]
  • [Cites] Clin Radiol. 1981 Nov;32(6):687-92 [7307442.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Oct;8(10):1699-703 [7153080.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2854-8 [10561362.001]
  • [Cites] Blood Rev. 2006 Nov;20(6):319-32 [16884838.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] Acta Oncol. 2004;43(8):758-65 [15764222.001]
  • [Cites] Int J Oncol. 2005 Apr;26(4):1093-9 [15754007.001]
  • [Cites] Oncology. 2004;67(3-4):211-4 [15557780.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):259-69 [10375083.001]
  • [Cites] Radiother Oncol. 1998 Oct;49(1):1-7 [9886690.001]
  • [Cites] Am J Clin Oncol. 1997 Feb;20(1):59-62 [9020290.001]
  • [Cites] J Urol. 1996 Mar;155(3):943-6 [8583613.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1361-7 [7751880.001]
  • [Cites] Eur J Cancer. 1994;30A(1):1-3 [8142148.001]
  • [Cites] Radiother Oncol. 1993 May;27(2):99-106 [8356234.001]
  • [Cites] Ann Oncol. 1990 Sep;1(5):383 [2261381.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):776-81 [3367185.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):297-302 [3339396.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):154-61 [10618618.001]
  • [Cites] Oncology. 2000 May;58(4):286-92 [10838493.001]
  • [Cites] Br J Urol. 1984 Oct;56(5):525-30 [6398719.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1313-9 [11697846.001]
  • [Cites] Clin Lymphoma. 2001 Jun;2(1):40-6 [11707869.001]
  • (PMID = 18020104.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC2574328
  •  go-up   go-down


8. Kato M, Soga N, Yamada Y, Kise H, Arima K, Sugimura Y: [A case of primary testicular malignant lymphoma associated with contralateral testicural recurrence after a seven-year interval]. Hinyokika Kiyo; 2007 Sep;53(9):671-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary testicular malignant lymphoma associated with contralateral testicural recurrence after a seven-year interval].
  • Right high ligation of testis was performed.
  • Pathological examination demonstrated a diffuse large B-cell lymphoma (DLBCL) originating from the right testis.
  • He underwent four courses of adjuvant chemotherapy consisting of CHOP (cyclophosphamide, doxorubicin, vincristin, prednisone) together with 40 Gy radiotherapy to the contralateral testis.
  • Following this treatment he achieved complete remission.
  • Seven years later in March 2006, he developed swelling of the left scrotum.
  • He underwent left high orchidectomy based on the suspicion of a contralateral testicular malignant lymphoma.
  • Pathological examination of the testicular specimen confirmed a diagnosis of DLBCL.
  • He underwent chemotherapy and has survived without evidence of recurrence.
  • We have summarized the cases of bilateral asynchrony primary testicular lymphoma.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933148.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 18
  •  go-up   go-down


9. Ponti G, Ponzoni M, Ferreri AJ, Foppoli M, Mazzucchelli L, Zucca E: The impact of histopathologic diagnosis on the proper management of testis neoplasms. Nat Clin Pract Oncol; 2008 Oct;5(10):619-22
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of histopathologic diagnosis on the proper management of testis neoplasms.
  • The patient did not receive the planned prophylactic radiotherapy and was treated with combined cisplatin, etoposide and bleomycin chemotherapy; after the completion of this treatment he achieved complete remission.
  • Three years later, and while still undergoing follow-up, the patient developed multiple neurological motor deficits.
  • DIAGNOSIS: Diffuse large B-cell lymphoma of the testis, relapsing in the central nervous system.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / diagnosis. Seminoma / drug therapy. Testicular Neoplasms / diagnosis. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Antigens, CD20 / metabolism. Bleomycin / administration & dosage. Brain / radiography. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Diagnosis, Differential. Etoposide / administration & dosage. Fatal Outcome. Humans. Immunohistochemistry. Interferon Regulatory Factors / metabolism. Male. Methotrexate / administration & dosage. Middle Aged. Orchiectomy. Recurrence. Remission Induction

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18725922.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4; 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Arkenau HT, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B, Trumper M, Norman A, Wotherspoon A, Horwich A: The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol; 2007 Mar;18(3):541-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
  • BACKGROUND: Relapse in the central nervous system (CNS) following initial treatment of diffuse large B-cell lymphoma (DLBCL) is an uncommon but serious complication.
  • Our institutional policy for patients at risk for CNS relapse was for IT chemoprophylaxis to be administered concurrently with systemic treatment.
  • Defined at-risk patients were those with lymphoma involvement at the following sites: bone marrow, testis, nasal/paranasal sinuses, orbits, bone/vertebrae and peripheral blood.
  • Three patients (1.1%) subsequently developed CNS relapse.
  • The median time from diagnosis of DLBCL to CNS relapse was 31.8 months (range 27.3-34.1 months).

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164228.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Lasota J, Nordling S, Miettinen M: Testicular diffuse large cell lymphoma with tubule preservation--molecular genetic evidence of transformation from previous follicular lymphoma. Virchows Arch; 2000 Mar;436(3):276-83
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular diffuse large cell lymphoma with tubule preservation--molecular genetic evidence of transformation from previous follicular lymphoma.
  • Testicular lymphomas usually occur in older men and are mostly diffuse large B-cell lymphomas (DLBL).
  • They may be primary manifestation of lymphoma or represent a relapse of a previous non-Hodgkin's lymphoma.
  • This report details a testicular large cell lymphoma, which was proven to be large cell transformation of a low-grade follicular lymphoma biopsied 8 years earlier.
  • Initially, a 38-year old man was diagnosed with cervical lymphadenopathy, and biopsy was interpreted as reactive follicular hyperplasia; no treatment was given, and the lymphadenopathy resolved spontaneously.
  • The patient died 7 months later with evidence for intra-abdominal and central nervous system lymphoma after a brief but temporary response to M-BACOD chemotherapy.
  • Orchiectomy specimen and gastroscopic biopsy showed diffuse large B-cell lymphoma (CD20+), which infiltrated between well-preserved tubules in the testis.
  • Histological comparison with 20 testicular lymphomas without previous lymphoma showed tubule infiltration in all cases, suggesting that the tubule-preserving infiltration pattern could be a histological marker for secondary lymphoma involvement in testis.
  • On re-examination, the lymph node 8 years prior was verified as follicular, predominantly small, cleaved cell lymphoma with bcl2-positive follicles.
  • The earlier follicular lymphoma and the subsequent diffuse large cell lymphoma were analyzed using polymerase chain reaction and showed identical sequences of the t(14;18) translocation and immunoglobulin heavy chain gene rearrangement.
  • Analysis of the VH-gene sequences from the follicular lymphoma revealed sequence heterogeneity consistent with ongoing mutation.
  • However, the transformed diffuse large cell lymphoma had no intraclonal variation, with the sequence matching with one of the subclones from the low-grade follicular lymphoma.
  • These results confirm that the large cell transformation of follicular lymphoma occurs in a single follicular lymphoma cell.
  • This case also indicates that the selection of the transformed clone can be part of the natural history of disease and can occur without exposure to chemotherapy.
  • [MeSH-major] Cell Transformation, Neoplastic. Genes, Immunoglobulin. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / genetics. Testicular Neoplasms / pathology
  • [MeSH-minor] Base Sequence. Cell Differentiation. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Gene Rearrangement, B-Lymphocyte. Humans. Immunoglobulin Heavy Chains / genetics. Male. Molecular Sequence Data. Polymerase Chain Reaction. Translocation, Genetic

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10782887.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


12. Koukourakis G, Kouloulias V: Lymphoma of the testis as primary location: tumour review. Clin Transl Oncol; 2010 May;12(5):321-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma of the testis as primary location: tumour review.
  • Non-Hodgkin's lymphoma as a primary testicular neoplasm accounts approximately 9% of all testicular malignant tumours and about 1-2% of all non-Hodgkin's lymphoma.
  • This neoplasm is the most common malignant tumour of the testis in the elderly.
  • The most common histotype in primary forms is the diffuse large B-cell lymphoma, whereas more aggressive histologies such as Burkitt's lymphoma are principal founded in cases of secondary involvement of the testis.
  • Despite the fact that responses to doxorubicin- containing chemotherapy, especially in early stages, show good results, relapses are often seen, and the prognosis of this tumour is very poor.
  • Testicular lymphoma often disseminates to other extranodal organs, such as contralateral testis, central nervous system (CNS), lung, pleura, Waldeyer's ring and soft tissue.
  • For patients with limited disease, the recommended first-line treatment is orchiectomy followed by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) combination chemotherapy, with central nervous system (CNS) prophylaxis and prophylactic irradiation of the contralateral testis.
  • In more advanced or relapsed disease, management should follow the worldwide recommendations for nodal diffuse large B-cell lymphoma (DLBCL).
  • [MeSH-major] Lymphoma / diagnosis. Lymphoma / therapy. Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):20-7 [12506165.001]
  • [Cites] Clin Lymphoma. 2001 Jun;2(1):40-6 [11707869.001]
  • [Cites] Br J Urol. 1974 Oct;46(5):569-75 [4420636.001]
  • [Cites] Neth J Med. 1991 Aug;39(1-2):92-100 [1961354.001]
  • [Cites] Acta Radiol Oncol Radiat Phys Biol. 1979;18(6):572-76 [543449.001]
  • [Cites] Am J Med. 1986 Sep;81(3):515-24 [3529957.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):197-204 [11773170.001]
  • [Cites] Blood. 2005 Jan 15;105(2):496-502 [15358629.001]
  • [Cites] Neurol Med Chir (Tokyo). 1986 Jan;26(1):68-70 [2425280.001]
  • [Cites] Oncology. 2000 May;58(4):286-92 [10838493.001]
  • [Cites] J Urol. 1969 Aug;102(2):230-2 [4895868.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1578-84 [6989476.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):154-61 [10618618.001]
  • [Cites] Clin Lymphoma. 2001 Sep;2(2):109-15 [11707851.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):652-6 [11849786.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):376-90 [8141430.001]
  • [Cites] Clin Lymphoma. 2002 Dec;3(3):167-72 [12521394.001]
  • [Cites] Australas Radiol. 1991 Aug;35(3):257-60 [1763988.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2854-8 [10561362.001]
  • [Cites] Ann Oncol. 1990 Sep;1(5):383 [2261381.001]
  • [Cites] J Urol. 1977 Nov;118(5):783-6 [916101.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):73-7 [7819053.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1361-7 [7751880.001]
  • [Cites] Eur Urol. 2000 Dec;38(6):774-7 [11111200.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):129-33 [14679132.001]
  • [Cites] J Urol. 1994 May;151(5):1162-70 [8158751.001]
  • [Cites] J Urol. 1996 Mar;155(3):943-6 [8583613.001]
  • [Cites] Radiother Oncol. 1993 May;27(2):99-106 [8356234.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1760-4 [7880601.001]
  • [Cites] J Pak Med Assoc. 1994 Apr;44(4):86-8 [8072129.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1182-6 [7850719.001]
  • [Cites] J Urol. 1977 Dec;118(6):1004-7 [336911.001]
  • [Cites] Int J Oncol. 2005 Apr;26(4):1093-9 [15754007.001]
  • [Cites] Nouv Rev Fr Hematol. 1995;37(5):267-72 [8700650.001]
  • [Cites] Oncology (Williston Park). 1998 Feb;12(2):185-91; discussion 192-5 [9507520.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Acta Oncol. 2004;43(8):758-65 [15764222.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):259-69 [10375083.001]
  • (PMID = 20466616.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 44
  •  go-up   go-down


13. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, Cortelazzo S, Ferreri AJ, Ambrosetti A, Martelli M, Thiéblemont C, Moreno HG, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, Oltean G, Callea V, Roy P, Cavalli F, Gospodarowicz MK, International Extranodal Lymphoma Study Group: Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol; 2003 Jan 1;21(1):20-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group.
  • PURPOSE: To determine clinical features and patterns of outcome of primary testicular diffuse large B-cell lymphomas (DLCL).
  • RESULTS: Most patients presented with localized disease (stage I to II), and the median age at diagnosis was 66 years (range, 19 to 91 years).
  • Anthracycline-based chemotherapy was administered to 255 patients (68%), and prophylactic intrathecal chemotherapy was given to 68 patients (18%); 133 patients (36%) received prophylactic scrotal radiotherapy.
  • A continuous risk of recurrence in the contralateral testis was seen in patients not receiving scrotal radiotherapy.
  • CONCLUSION: Testicular DLCL is characterized by a particularly high risk of extranodal relapse even in cases with localized disease at diagnosis.
  • Anthracycline-based chemotherapy, CNS prophylaxis, and contralateral testicular irradiation seem to improve the outcome.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Disease-Free Survival. Humans. Male. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12506165.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Link MP, Devidas M, Murphy SB, Behm FG, Hutchison R: Favorable treatment outcome of children with early stage large B-cell and anaplastic large cell lymphomas. J Clin Oncol; 2004 Jul 15;22(14_suppl):8500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable treatment outcome of children with early stage large B-cell and anaplastic large cell lymphomas.
  • Large cell lymphomas (LCL) are relatively rare in children and sub-divided among diffuse large B-cell lymphomas (DLBCL), anaplastic large cell lymphomas (ALCL), peripheral T (PT) and other rare subtypes.
  • One hundred fifty-six (40%) had large cell lymphoma.
  • All patients received nine weeks of chemotherapy including vincristine 1.5mg/m2 weekly for seven doses; doxorubicin 40mg/m2 and cyclophosphamide 750mg/m2 on days 1, 22 and 43; and prednisone 40mg/m2 daily for 28 days during the first 4 weeks and on days 43-47.
  • Among children with DLBCL, primary sites included lymph nodes (13), GI tract (8), bone (8), tonsil (8), testis (3), and other (6).
  • Only one patient with DLBCL developed recurrent disease and died.
  • At 5 years, the projected event-free survival (EFS) is 98 % (SE 3%), and the overall survival (OS), 98 % (SE 3%).
  • Thirty-five children with ALCL (60%) had T cell markers, and the remainder had null cell markers.
  • Nine patients with ALCL (T=5; null=4) failed treatment: three failed induction, and six relapsed from complete remission, but were effectively salvaged.
  • The projected 5 year EFS for early stage ALCL is 84 % (SE 7%) (DLBCL versus ALCL, p-value 0.02); the OS, 100%.
  • CONCLUSIONS: Nine weeks of modest intensity chemotherapy are sufficient for children with early stage DLBCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014540.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kato N, Mizuno O, Ito K, Kimura K, Shibata M: Neutrophil-rich anaplastic large cell lymphoma presenting in the skin. Am J Dermatopathol; 2003 Apr;25(2):142-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophil-rich anaplastic large cell lymphoma presenting in the skin.
  • A neutrophil-rich anaplastic large cell lymphoma (ALCL) presented in the skin of a 47-year-old Japanese woman.
  • Histologically, it showed a proliferation of pleomorphic, anaplastic, large tumor cells with nuclei of various shapes, including embryo-shaped, Reed-Sternberg cell-like binucleated, and wreath-shaped multiple nuclei, in the dermis and subcutaneous tissues.
  • Immunophenotypically, the neoplastic cells were positive for CD30, CD4, leukocyte common antigen, anaplastic lymphoma kinase-1, epithelial membrane antigen, and granzyme B.
  • Six and a half months after diagnosis, however, swelling of a left axillary lymph node appeared; it also showed a proliferation of anaplastic large tumor cells admixed with numerous neutrophils ranging from about 25% to more than 60% per field.
  • Southern blot analysis of T-cell receptor gene rearrangement revealed a clonal band.
  • The patient was treated with six courses of cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy with complete remission.
  • Seventeen cases of neutrophil-rich ALCL arising in the skin, lymph node, muscle, testis, and skull bone were reviewed.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Neutrophils / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12652196.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antigens, CD4; 0 / Biomarkers, Tumor; 0 / Mucin-1; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.1.3.48 / Antigens, CD45
  • [Number-of-references] 26
  •  go-up   go-down


18. Kim YB, Chang SK, Yang WI, Hahn JS, Koom WS, Shim SJ, Park W, Lee KK, Suh CO, Kim GE: Primary NK/T cell lymphoma of the testis. A case report and review of the literature. Acta Haematol; 2003;109(2):95-100
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary NK/T cell lymphoma of the testis. A case report and review of the literature.
  • We report a case of aggressive 'nasal type' natural killer (NK)/T cell lymphoma initially presenting as a testicular tumor in a Korean man, which quickly took a fatal course by widespread dissemination.
  • Histologically, the testicular mass showed a diffuse dense infiltrate of medium-sized and atypical large lymphoid cells with angiocentric and angiodestructive infiltration and areas of coagulative necrosis on hematoxylin-eosin stained sections.
  • Immunophenotyping by immunohistochemistry yielded surface markers consistent with NK/T cell lymphoma.
  • During involved-field irradiation and chemotherapy following radical orchiectomy, the tumor disseminated shortly to the skin and soft tissue of his anterior chest wall and central nervous system (CNS).
  • To the best of our knowledge, this is the 9th reported case of confirmed NK/T cell lymphoma arising from the testis.
  • Relevant literature is reviewed, and the clinicopathologic features, natural history, and treatment options for primary testicular NK/T cell lymphoma are discussed.
  • [MeSH-major] Killer Cells, Natural. Lymphoma, T-Cell / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System / pathology. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Fatal Outcome. Herpesvirus 4, Human / genetics. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization. Male. Methotrexate / therapeutic use. Middle Aged. Necrosis. Neoplasm Metastasis. Orchiectomy. Prednisone / therapeutic use. RNA, Viral / analysis. Radiotherapy. Recurrence. Skin / pathology. Thoracic Wall / pathology. Tomography, X-Ray Computed. Ultrasonography. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12624494.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / RNA, Viral; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol
  • [Number-of-references] 16
  •  go-up   go-down


19. Vitolo U, Ferreri AJ, Zucca E: Primary testicular lymphoma. Crit Rev Oncol Hematol; 2008 Feb;65(2):183-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular lymphoma.
  • Primary non-Hodgkin's lymphoma of the testis (PTL) accounts for about 9% of testicular neoplasms and 1-2% of all non-Hodgkin's lymphomas.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common histotype in primary forms; aggressive histologies, especially Burkitt's lymphoma, are prevalent in cases of secondary involvement of testis.
  • Although good results with doxorubicin-containing chemotherapy, followed or not by radiotherapy, have been reported, a high proportion of patients with stage I-II diseases experience aggressive relapses, and patients with advanced disease have a very poor prognosis.
  • PTL has a propensity to disseminate to other extranodal organs, including the controlateral testis, CNS, skin, Waldeyer's ring, lung, pleura, and soft tissue.
  • Orchidectomy followed by R-CHOP combination, with CNS prophylaxis, and prophylactic irradiation of the contralateral testis is the recommended first-line treatment for patients with limited disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Testicular Neoplasms

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962036.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 40
  •  go-up   go-down


20. Linassier C, Desablens B, Lefrancq T, Le Prise PY, Harousseau JL, Jacob C, Gandhour C, Haillot O, Lucas V, Leloup R, Escoffre M, Colombat P, Tabuteau S, GOELAMS Study Group: Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group. Clin Lymphoma; 2002 Dec;3(3):167-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group.
  • Sixteen patients with aggressive primary testicular involvement were analyzed separately from a prospective multicenter series of 494 patients with stage I/II aggressive nonlymphoblastic lymphoma.
  • The treatment strategy included 3 cycles of anthracycline-based chemotherapy followed by regional radiation therapy on inguinal, iliac, and para-aortic lymph nodes and central nervous system (CNS) prophylaxis by intrathecal chemotherapy and brain irradiation.
  • Chemotherapy was stratified by age group.
  • Patients aged 18-60 years received the Groupe Ouest Est d'Etude des Leucemies Aigues et Maladies du Sang (GOELAMS) 02 protocol: 3 monthly cycles of VCAP (vindesine 3 mg/m2 day 1, doxorubicin 80 mg/m2 day 2, cyclophosphamide 1500 mg/m2 day 2, and prednisone 80 mg/m2 days 1-5).
  • The histological subtypes were diffuse large-cell lymphoma in all cases.
  • One patient died from septic shock during the last course of chemotherapy.
  • Relapse in the CNS occurred in only 1 patient and in the contralateral testis in 1 patient.
  • This is the first report of a prospective study in which treatment of testicular non-Hodgkin's lymphoma was precisely defined at diagnosis.
  • Compared to other series, a combination of orchiectomy with 3 cycles of CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone)-derived chemotherapy, regional radiation therapy, and CNS prophylaxis seems to improve prognosis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Brain / radiation effects. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Epirubicin / therapeutic use. Humans. Lymph Nodes / pathology. Male. Middle Aged. Prednisone / therapeutic use. Prognosis. Prospective Studies. Recurrence. Time Factors. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Lymphoma. 2002 Dec;3(3):173-4 [12521395.001]
  • (PMID = 12521394.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEV protocol; CHOP protocol
  •  go-up   go-down


21. Lagmay J, Termuhlen A, Fung B, Ranalli M: Primary testicular presentation of ALK-1-negative anaplastic large cell lymphoma in a pediatric patient. J Pediatr Hematol Oncol; 2009 May;31(5):330-2
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular presentation of ALK-1-negative anaplastic large cell lymphoma in a pediatric patient.
  • Anaplastic large cell lymphoma is a heterogeneous group of malignant non-Hodgkin lymphomas that occurs in up to 15% of all pediatric non-Hodgkin lymphomas.
  • It is characterized by B-symptoms and involvement of extranodal sites such as skin, bone, and soft tissue.
  • This brief report describes first reported case of pediatric primary testicular anaplastic large cell lymphoma in a 14-year-old boy.
  • After chemotherapy and unilateral radical orchiectomy, patient continues in complete remission.
  • [MeSH-major] Activin Receptors, Type II / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / metabolism. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antigens, CD30 / metabolism. Biomarkers, Tumor / metabolism. Biopsy. Cell Nucleus / metabolism. Cell Nucleus / pathology. Golgi Apparatus / metabolism. Golgi Apparatus / pathology. Humans. Male. Orchiectomy. Testis / pathology. Testis / surgery

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415011.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


22. Lagrange JL, Ramaioli A, Theodore CH, Terrier-Lacombe MJ, Beckendorf V, Biron P, Chevreau CH, Chinet-Charrot P, Dumont J, Delobel-Deroide A, D'Anjou J, Chassagne C, Parache RM, Karsenty JM, Mercier J, Droz JP, Radiation Therapy Group and the Genito-Urinary Group of the French Federation of Cancer Centres: Non-Hodgkin's lymphoma of the testis: a retrospective study of 84 patients treated in the French anticancer centres. Ann Oncol; 2001 Sep;12(9):1313-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the testis: a retrospective study of 84 patients treated in the French anticancer centres.
  • Primary non-Hodgkin's lymphoma of the testicle is rare.
  • Diffuse large B-cell lymphoma was diagnosed in 75% of cases.
  • Treatment included orchidectomy and radiotherapy and/or chemotherapy.
  • Among patients presenting stage I disease, no difference was found between those treated with combined surgery and chemotherapy or surgery followed or not followed by radiotherapy.
  • This study confirms that non-Hodgkin's lymphoma of the testicle carries a poor prognosis.
  • Systemic adjuvant chemotherapy should be discussed because of the high recurrence rate.
  • Inclusion of these cases in large co-operative prospective studies is recommended.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11697846.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Tagami K, Tanda S, Tokumura H, Yamaguchi M: [A case of triple malignant tumors consisting of esophagus, stomach and malignant lymphoma with a histopathological feature of collision between gastric cancer and malignant lymphoma--a case report]. Gan To Kagaku Ryoho; 2010 Dec;37(13):2891-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of triple malignant tumors consisting of esophagus, stomach and malignant lymphoma with a histopathological feature of collision between gastric cancer and malignant lymphoma--a case report].
  • We report a rare case of a collision between a gastric cancer and a malignant lymphoma with a wide systemic metastasis, combined with esophagus cancer, stomach cancer and malignant lymphoma.
  • A 73-year-old man complained of gross hematuria and swelling of the right testis.
  • He was diagnosed with malignant diffuse large B cell lymphoma by immunostaining from the extirpated right testis.
  • He received six cycles of R-CHOP therapy.
  • Thereafter, we performed MTX-HOPE therapy as a salvage therapy for four cycles.
  • During this chemotherapy, he felt epigastralgia; esophagus cancer (squamous cell carcinoma) and stomach cancer (highly-differentiated adenocarcinoma) were found by upper endoscopy.
  • However, the gastrointestinal cancer was inoperable, since the malignant lymphoma was progressive.
  • His general status had been exacerbated, and he died about one year after he was diagnosed with malignant lymphoma.
  • Pathological examination revealed that the adenocarcinoma had partly collided with the malignant lymphoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160264.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Maruyama T, Hashimoto T, Suzuki T, Ueda Y, Higuchi Y, Qui J, Kondou N, Nojima M, Yamamoto S, Shima H, Hirota S, Okada M: [A case of primary testicular malignant lymphoma associated with contralateral testicular recurrence after a nine-year interval: a case report]. Hinyokika Kiyo; 2009 Oct;55(10):639-43
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary testicular malignant lymphoma associated with contralateral testicular recurrence after a nine-year interval: a case report].
  • Pathological examination demonstrated a diffuse large B-cell lymphoma (DLBCL) originating from the left testis, and then he underwent 5 courses of chemotherapy consisting of THP-COP (THP-adriamycin, cyclophosphamide, vincristin, predonisone).
  • Following the treatment for five years, he had no evidence of recurrence.
  • He underwent right high orchiectmy with suspicion of a contralateral testicular malignant lymphoma.
  • He underwent chemotherapy (rituximab-THP-COP) and achieved complete remission again.
  • He is doing well without recurrence of disease for three years after the last treatment.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Male. Neoplasm Recurrence, Local. Time Factors

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926952.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 28
  •  go-up   go-down


25. Kondo T, Wada H, Yata K, Mikami M, Tsujioka T, Suemori S, Suetsugu Y, Nakanishi H, Otsuki T, Yamada O, Yawata Y, Morioka M, Tanaka H, Sadahira Y, Sugihara T: [Seven patients with stage I and II primary testicular lymphoma]. Rinsho Ketsueki; 2002 Jun;43(6):473-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Seven patients with stage I and II primary testicular lymphoma].
  • Seven patients with stage I and II primary testicular lymphoma (PTL) have been treated since 1990 to the present at Kawasaki Medical School.
  • The histological diagnosis was diffuse large B-cell type in all patients.
  • After high-orchiectomy for resection of tumor, two patients received chemotherapy alone, with a combination of chemotherapy and irradiation of the contralateral testis in the remaining five.
  • As it is recognized that, even in localized stage or low risk group PTL patients, the relapse rate in the central nervous system (CNS) and contralateral testis is quite high, chemotherapy, prophylactic CNS treatment and radiation of the contralateral testis after tumor resection should be included in the management of PTL.
  • [MeSH-major] Lymphoma, B-Cell. Lymphoma, Large B-Cell, Diffuse. Testicular Neoplasms
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Orchiectomy. Prednisone / administration & dosage. Prognosis. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12134704.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


26. Chierigo P, Nicolardi L, Rahmati M, Lazzarotto M, Brotza D, Bassan F, Franzolin N: [Testicular localization of extranodal multifocal non-Hodgkin lymphoma. Report of two cases, review of the literature and clinical considerations]. Urologia; 2009 Apr-Jun;76(2):133-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular localization of extranodal multifocal non-Hodgkin lymphoma. Report of two cases, review of the literature and clinical considerations].
  • The aim of our study is to describe two cases of testicular localization of non- Hodgkin Lymphoma associated with the involvement of other extranodal organs, and to investigate the possible causes of this association according to the evidences found in literature.
  • Non-Hodgkin Lymphoma is extranodal in 25% of cases.
  • Most of the times the organs involved are stomach, bowel, skin, central nervous system.
  • About urological localizations, the most common is testis.
  • Very rare is to find lymphoma in kidney, prostate, urinary bladder, and ureter.
  • Testicular lymphoma is about 5% of testis malignancies; it is more frequent in the 7th and in the 8th decade.
  • Metastases of testicular non-Hodgkin lymphoma are described also many years later, and also in distant organs.
  • Primary forms are usually "diffuse large B cell", a high-grade histotype; metastatic ones often show Burkitt cells.
  • The standard therapy used for non-Hodgkin Lymphomas does not reach testis and central nervous system, so that these sites are called "Therapeutic Shrines".
  • Therefore, in order to prevent testicular localization, it is necessary to use radiotherapy, and for nervous system prophylaxis it is necessary to administer intrathecal chemotherapy.
  • More than one localization of non-Hodgkin lymphoma simultaneously found may indicate not only a metastatic spread, but also a multicentric origin.
  • We describe two patients who had one testis removed because of a big mass that turned out to be a non-Hodgkin lymphoma.
  • The first patient had been treated for a non-Hodgkin lymphoma of maxillary sinus 20 months before.
  • In both cases the different localizations of non-Hodgkin lymphoma showed the same histological features and cellular immunophenotype.
  • It is important to underline that in the former patient staging TC, repeated many times, had always been negative, but physical examination of testis had been omitted, so that sinonasal localization, assumed to be the first one, really might have been the spread of an undetected testis lymphoma.
  • In conclusion, in case of extranodal non- Hodgkin lymphoma or any other malignancies, manual or ultrasound examination of testis should never be omitted, because standard techniques of staging (TC, RMN, PET) cannot explore this organ.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086316.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Hasselblom S, Ridell B, Wedel H, Norrby K, Sender Baum M, Ekman T: Testicular lymphoma--a retrospective, population-based, clinical and immunohistochemical study. Acta Oncol; 2004;43(8):758-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular lymphoma--a retrospective, population-based, clinical and immunohistochemical study.
  • From a population-based registry, 35 patients with histologically verified testicular lymphomas were identified: diffuse large B-cell lymphomas (DLBCL) in 33 and peripheral T-cell lymphomas in two cases.
  • Twenty-eight patients received systemic chemotherapy, 17 of whom also received intrathecal prophylaxis, and 12 out of these 17 also received radiotherapy to the contralateral testis.
  • Immunohistochemical analysis of the DLBCL tumours revealed that 31% had the germinal centre B-cell-like phenotype.
  • [MeSH-major] Cause of Death. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / mortality. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Probability. Proportional Hazards Models. Radiotherapy, High-Energy / methods. Registries. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764222.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


28. Zucca E, Gregorini A, Cavalli F: Management of non-Hodgkin lymphomas arising at extranodal sites. Ther Umsch; 2010 Oct;67(10):517-25
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary extranodal lymphomas are relatively rare non-Hodgkin lymphoma presentations with either no or only "minor" nodal involvement along with a clinically "dominant" extranodal component, to which primary treatment must often be directed.
  • In principle, as for primary nodal disease, treatment strategies depends on the patient's clinical conditions, the extent and/or location of the disease, and the histological type.
  • In general, for stage I and II disease with low tumor burden, local therapy is a relevant option both for cure and local control.
  • Localizations with particularly poor survival are the enteropathy-type T-cell lymphoma, the primary testicular diffuse large B-cell lymphoma, and the primary CNS Lymphoma.
  • However, recent studies have shown that site-tailored treatment strategies in testis and brain lymphoma may result in a significant outcome improvement.
  • Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is the most common indolent subtype.
  • This lymphoma usually arises in mucosal sites where lymphocytes are not normally present and where a lymphoid infiltration is acquired in response to either chronic infectious conditions or autoimmune processes: Helicobacter pylori gastritis, Hashimoto's thyroiditis, Sjögren syndrome.
  • Indeed, a pathogenetic link between gastric MALT lymphoma and H. pylori is strongly suggested by the regression of gastric MALT lymphoma (in approx.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Combined Modality Therapy. Disease Progression. Drug Delivery Systems. Humans. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20886458.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement